Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model.
- 1999-09
- Gastroenterology 117(3)
- M. Caplan
- R. Miller-Catchpole
- S. Kaup
- Tanya Russell
- Matthew J Lickerman
- M. Amer
- Yu Xiao
- R. Thomson
- PubMed: 10464133
- DOI: 10.1016/S0016-5085(99)70450-6
Abstract
Background & aims: Neonatal necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease of premature infants partly caused by intestinal bacterial proliferation. Because bifidobacteria are thought to reduce the risk for intestinal disturbances associated with pathogenic bacterial colonization, we hypothesized that exogenous bifidobacterial supplementation to newborn rats would result in intestinal colonization and a reduction in the incidence of neonatal NEC.
Methods: Newborn rat pups were given Bifidobacterium infantis (10(9) organisms per animal daily), Escherichia coli, or saline control and exposed to the NEC protocol consisting of formula feeding (Esbilac; 200 cal. kg(-1). day(-1)) and asphyxia (100% N(2) for 50 seconds followed by cold exposure for 10 minutes). Outcome measures included stool and intestinal microbiological evaluation, gross and histological evidence of NEC, plasma endotoxin concentration, intestinal phospholipase A(2) expression, and estimation of intestinal mucosal permeability.
Results: Bifidobacterial supplementation resulted in intestinal colonization by 24 hours and appearance in stool samples by 48 hours. Bifidobacteria-supplemented animals had a significant reduction in the incidence of NEC compared with controls and E. coli-treated animals (NEC, 7/24 B. infantis vs. 19/27 control vs. 16/23 E. coli; P < 0.01). Plasma endotoxin and intestinal phospholipase A(2) expression were lower in bifidobacteria-treated pups than in controls, supporting the role of bacterial translocation and activation of the inflammatory cascade in the pathophysiology of NEC.
Conclusions: Intestinal bifidobacterial colonization reduces the risk of NEC in newborn rats.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium | Reduced Intestinal Phospholipase A2 Expression | Beneficial | Moderate |
Bifidobacterium | Reduced Occurrence of Necrotizing Enterocolitis | Beneficial | Large |
Bifidobacterium | Reduced Plasma LPS Levels | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Intestinal Phospholipase A2 Expression | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Plasma Endotoxin Concentration | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Risk of Necrotizing Enterocolitis | Beneficial | Large |
Bifidobacterium infantis BI02 | Reduced Intestinal Phospholipase A2 Expression | Beneficial | Moderate |
Bifidobacterium infantis BI02 | Reduced Plasma LPS Levels | Beneficial | Moderate |
Bifidobacterium infantis BI02 | Reduced Risk of Necrotizing Enterocolitis | Beneficial | Large |
Bifidobacterium infantis SD-6720 | Reduced Intestinal Phospholipase A2 Expression | Beneficial | Moderate |
Bifidobacterium infantis SD-6720 | Reduced Plasma Endotoxin Concentration | Beneficial | Moderate |
Bifidobacterium infantis SD-6720 | Reduced Risk of Necrotizing Enterocolitis | Beneficial | Large |